152 related articles for article (PubMed ID: 29515110)
1. Raddeanin A suppresses breast cancer-associated osteolysis through inhibiting osteoclasts and breast cancer cells.
Wang Q; Mo J; Zhao C; Huang K; Feng M; He W; Wang J; Chen S; Xie Z; Ma J; Fan S
Cell Death Dis; 2018 Mar; 9(3):376. PubMed ID: 29515110
[TBL] [Abstract][Full Text] [Related]
2. Dihydroartemisinin prevents breast cancer-induced osteolysis via inhibiting both breast caner cells and osteoclasts.
Feng MX; Hong JX; Wang Q; Fan YY; Yuan CT; Lei XH; Zhu M; Qin A; Chen HX; Hong D
Sci Rep; 2016 Jan; 6():19074. PubMed ID: 26743690
[TBL] [Abstract][Full Text] [Related]
3. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
4. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract][Full Text] [Related]
5. Pogostone attenuates osteolysis in breast cancer by inhibiting the NF-kB and JNK signaling pathways of osteoclast.
Zheng T; Lin Z; Jiang G; Chen H; Yang Y; Zeng X
Life Sci; 2023 Sep; 328():121611. PubMed ID: 37068706
[TBL] [Abstract][Full Text] [Related]
6. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
[TBL] [Abstract][Full Text] [Related]
7. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
[TBL] [Abstract][Full Text] [Related]
8. Platycodin D Blocks Breast Cancer-Induced Bone Destruction by Inhibiting Osteoclastogenesis and the Growth of Breast Cancer Cells.
Lee SK; Park KK; Kim HJ; Kim KR; Kang EJ; Kim YL; Yoon H; Kim YS; Chung WY
Cell Physiol Biochem; 2015; 36(5):1809-20. PubMed ID: 26184636
[TBL] [Abstract][Full Text] [Related]
9. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
10. Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model.
Xiao F; Zhai Z; Jiang C; Liu X; Li H; Qu X; Ouyang Z; Fan Q; Tang T; Qin A; Gu D
Exp Cell Res; 2015 Jan; 330(1):91-101. PubMed ID: 25016282
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
12. Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling.
Yang Q; Guo J; Zheng J; Chen Y; Zou B; Li R; Ding Z; Wang Y; Li L; Chen Z; Mo L; Liang Q; Chen F; Li X
Int Immunopharmacol; 2023 Jul; 120():110316. PubMed ID: 37253315
[TBL] [Abstract][Full Text] [Related]
13. Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo.
Li Z; Li D; Chen X
Med Sci Monit; 2018 Feb; 24():1044-1053. PubMed ID: 29459582
[TBL] [Abstract][Full Text] [Related]
14. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
15. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
16. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
[TBL] [Abstract][Full Text] [Related]
17. 2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo.
Snoeks TJ; Mol IM; Que I; Kaijzel EL; Löwik CW
Mol Cancer Ther; 2011 May; 10(5):874-82. PubMed ID: 21422268
[TBL] [Abstract][Full Text] [Related]
18. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.
Ouyang Z; Zhai Z; Li H; Liu X; Qu X; Li X; Fan Q; Tang T; Qin A; Dai K
Biochem Pharmacol; 2014 Aug; 90(3):276-87. PubMed ID: 24950468
[TBL] [Abstract][Full Text] [Related]
19. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
